UnitedHealth (UNH) Has Strong 3Q & Pfizer (PFE) Nears Lows As Vaccine Demand Falls

Adolf Goebbels
Published on Oct 23, 2023
UBS upgraded UnitedHealth (UNH) to buy from neutral. The analyst notes that UNH’s “strong” 3Q is a “clearing event that should pave the way for improved valuation.” UBS raised UNH’s price target to $640 from $520. Jenny Horne discusses this along with Pfizer (PFE) which cut its full-year guidance as demand for Covid-19 vaccines fall. PFE’s shares are near a 52-week low. Tune in to find out more about the stock market today.

#pfizer #stocks #investing #unitedhealth #trading #healthcare #vaccine #stockmarket #wallstreet #money #finance #businessnews #news